Congress approved language in the spending bill that makes FDA-approved multi-cancer early detection (MCED) tests eligible for Medicare coverage, removing the prior requirement for USPSTF endorsement. The provision ties reimbursement to rates similar to multi-target stool DNA colorectal tests and phases in eligibility beginning in 2029 for people aged 50–65. The move addresses a long-standing industry priority and could materially expand market access for MCED developers. Exact Sciences and other diagnostics firms praised the change; commercial uptake and pricing negotiations will now be central to MCED commercialization strategies.